Alternatively, ATR kinase inhibitors (AZD6738 and VE-821) sensitize cancer cells to T-cell killing by downregulating the cell surface expression of PD-L1 in a proteasome-dependent manner to attenuate the PD-L1/PD-1 interaction in MDA-MB-231 BC cells [108]. This evidence concerns the gene CD274 and breast cancer.